

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ARCH Venture Partners VIII, LLC</u>  (Last) (First) (Middle) 8755 WEST HIGGINS ROAD SUITE 1025  (Street) CHICAGO IL 60631  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Twist Bioscience Corp [ TWST ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 11/02/2018	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/02/2018		C		1,182,645	A	(1)	1,182,645	I	See footnote(2)(3)
Common Stock	11/02/2018		C		718,275	A	(1)	1,900,920	I	See footnote(2)(3)
Common Stock	11/02/2018		C		266,776	A	(1)	2,167,696	I	See footnote(2)(3)
Common Stock	11/02/2018		C		224,726	A	(1)	2,392,422	I	See footnote(2)(3)
Common Stock	11/02/2018		P		15,000(4)	A	\$14	2,407,422	I	See footnote(2)(3)
Common Stock	11/02/2018		C		894,146	A	(1)	894,146	I	See footnote(5)(3)
Common Stock	11/02/2018		P		60,000(4)	A	\$14	954,146	I	See footnote(5)(3)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	11/02/2018		C		1,182,645		(1)	(6)	Common Stock	1,182,645	(1)	0	I	See footnote(2)(3)
Series B Preferred Stock	(1)	11/02/2018		C		718,275		(1)	(6)	Common Stock	718,275	(1)	0	I	See footnote(2)(3)
Series C Preferred Stock	(1)	11/02/2018		C		266,776		(1)	(6)	Common Stock	266,776	(1)	0	I	See footnote(2)(3)
Series D Preferred Stock	(1)	11/02/2018		C		224,726		(1)	(6)	Common Stock	224,726	(1)	0	I	See footnote(2)(3)
Series D Preferred Stock	(1)	11/02/2018		C		894,146		(1)	(6)	Common Stock	894,146	(1)	0	I	See footnote(5)(3)

1. Name and Address of Reporting Person\*  
ARCH Venture Partners VIII, LLC  
  
 (Last) (First) (Middle)  
 8755 WEST HIGGINS ROAD  
 SUITE 1025  
  
 (Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[ARCH Venture Fund VII, L.P.](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD  
SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[ARCH Venture Fund VIII Overage, L.P.](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD  
SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[ARCH Venture Partners VII, L.P.](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD  
SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[ARCH Venture Partners VII, LLC](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD  
SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[BYBEE CLINTON](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD  
SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[NELSEN ROBERT](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD  
SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

**Explanation of Responses:**

1. Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis.
2. The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
3. Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
4. Reflects shares purchased in the Issuer's initial public offering.
5. The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
6. The expiration date is not relevant to the conversion of these securities.

**Remarks:**

/s/ Mark McDonnell, Attorney-  
in-Fact for Keith Crandell,  
Managing Director of ARCH  
Venture Partners VII, LLC, 11/06/2018  
General Partner of ARCH  
Venture Partners VII, L.P.,  
General Partner of ARCH  
Venture Fund VII, L.P.

/s/ Mark McDonnell, Attorney-  
in-Fact for Keith Crandell,  
Managing Director of ARCH  
Venture Partners VIII, LLC, 11/06/2018  
General Partner of ARCH  
Venture Fund VIII Overage, L.P.

/s/ Mark McDonnell, Attorney-  
in-Fact for Keith Crandell,  
Managing Director of ARCH  
Venture Partners VII, LLC, 11/06/2018  
General Partner of ARCH  
Venture Partners VII, L.P.

/s/ Mark McDonnell, Attorney-  
in-Fact for Keith Crandell,  
Managing Director of ARCH  
Venture Partners VII, LLC 11/06/2018

/s/ Mark McDonnell, Attorney-  
in-Fact for Keith Crandell,  
Managing Director of ARCH  
Venture Partners VIII, LLC 11/06/2018

/s/ Mark McDonnell, Attorney-  
in-Fact for Clinton Bybee 11/06/2018

/s/ Mark McDonnell, Attorney-  
in-Fact for Robert Nelsen 11/06/2018

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**